The most extensively referenced missing concept in this wiki. SCFAs -- acetate (C2), propionate (C3), and butyrate (C4) -- are the primary metabolic products of anaerobic bacterial fermentation of dietary fiber in the colon. They serve as the critical molecular link between diet, the gut microbiome, and host physiology. Their depletion is a near-universal feature of every disease covered in this wiki.
Production and Producers
Acetate (C2)
- Most abundant SCFA in the colon (~60% of total); produced by many genera including bifidobacterium, Bacteroides, Prevotella, and Ruminococcus via the Wood-Ljungdahl pathway or pyruvate decarboxylation.
- Enters systemic circulation and is used as substrate by peripheral tissues and as a precursor for butyrate via cross-feeding.
Propionate (C3)
- Produced primarily via the succinate pathway by Bacteroides, Dialister, Veillonella, and Phascolarctobacterium; also via the acrylate and propanediol pathways by akkermansia muciniphila and Roseburia inulinivorans.
- Absorbed and largely cleared by the liver; regulates gluconeogenesis and cholesterol synthesis.
Butyrate (C4)
- The most biologically potent SCFA. Produced via butyryl-CoA:acetate CoA-transferase pathway by faecalibacterium prausnitzii, Roseburia, blautia, Eubacterium rectale, and Coprococcus.
- Primary energy source for colonocytes (~70% of their energy); maintains epithelial integrity.
Receptor Signaling
- GPR43 (FFAR2): Activated by acetate and propionate. Expressed on immune cells, enteroendocrine cells. Drives anti-inflammatory responses; stimulates GLP-1 and PYY secretion.
- GPR41 (FFAR3): Activated by propionate and butyrate. Expressed on enteric neurons and sympathetic ganglia. Regulates gut motility, energy expenditure, and blood pressure via Olfr78 counter-regulation [hoffelner 2025 emerging therapy targets microbiome cvd].
- GPR109A (HCAR2): Activated by butyrate and niacin. Expressed on colonocytes, macrophages, dendritic cells. Promotes Treg differentiation and IL-10 production; suppresses NF-kB.
Epigenetic Mechanism: HDAC Inhibition
Butyrate is the most potent SCFA inhibitor of histone deacetylases (HDACs), particularly class I and II. This produces broad anti-inflammatory and anti-proliferative effects:
- Upregulates Foxp3 expression, driving naive T cell differentiation into regulatory T cells (Tregs) that suppress autoimmunity and inflammation.
- Inhibits NF-kB activation in macrophages, reducing TNF-alpha and IL-6 production.
- Promotes expression of tight junction proteins (claudins, occludin, ZO-1) in colonocytes.
- Inhibits cancer cell proliferation and induces apoptosis -- the basis of butyrate's protective role against colorectal cancer.
Gut Barrier Maintenance
SCFAs -- especially butyrate -- are essential for intestinal barrier integrity:
- Provide 60-70% of colonocyte energy via beta-oxidation, maintaining the metabolic health of the epithelium.
- Stimulate mucin production by goblet cells.
- Upregulate tight junction protein expression via HDAC inhibition and AMPK activation.
- Maintain the hypoxic environment of the colonic crypt necessary for anaerobic commensal survival (see hypoxic signaling).
SCFAs in Neuroinflammation and the Gut-Brain Axis
- Butyrate modulates neuroinflammation by reducing microglial activation and shifting microglia from pro-inflammatory M1 to anti-inflammatory M2 phenotype [sun 2025 sodium butyrate neuroinflammation cardiac arrest].
- SCFAs signal to the brain via vagal afferents (GPR41/43 on enteric neurons) and via systemic circulation crossing the blood-brain barrier [bao 2024 iron homeostasis intestinal immunity gut microbiota].
- Reduced fecal SCFAs documented in ASD, with altered profiles correlating with GI symptoms and behavioral severity [he 2023 altered gut microbiota scfa constipated asd chinese, liu 2019 altered gut microbiota scfa chinese children asd].
The Metal-SCFA Vicious Cycle
This is the most critical metal connection in the wiki:
1. Metal exposure (Cd, Ni, Pb, Hg, As) selectively eliminates SCFA-producing bacteria -- Roseburia, faecalibacterium prausnitzii, bifidobacterium -- which are metal-sensitive obligate anaerobes [pendergrass 2026 heavy metals obesity epidemic].
2. SCFA depletion compromises gut barrier integrity (reduced butyrate for colonocytes, reduced tight junction expression).
3. Barrier failure increases paracellular permeability to bacterial LPS, food antigens, AND the metals themselves.
4. Increased metal absorption further damages SCFA producers, completing the vicious cycle.
5. Systemic consequences: LPS translocation activates inflammation via TLR4/nf kappa b; reduced Treg induction permits autoimmunity; loss of colonocyte energy shifts metabolism.
This cycle operates in virtually every disease in the wiki -- from inflammatory bowel disease and cardiovascular disease to alzheimers disease, parkinsons disease, autism spectrum disorder, and obesity.
SCFAs and Blood Pressure Regulation
SCFAs regulate blood pressure through opposing receptor systems:
- GPR41: propionate binding causes vasodilation and BP reduction.
- Olfr78: propionate/acetate binding on renal juxtaglomerular cells stimulates renin release, raising BP.
- Net effect depends on SCFA concentration and receptor balance; SCFA depletion from dysbiosis generally associates with hypertension [hoffelner 2025 emerging therapy targets microbiome cvd].
Connections
- gut metal microbiome -- the ecosystem where metal-driven SCFA depletion occurs
- dysbiosis -- loss of SCFA producers is the functional consequence of dysbiosis
- inflammation -- SCFA depletion removes anti-inflammatory brake (Tregs, HDAC inhibition)
- gut brain axis -- SCFAs are key mediators of gut-to-brain signaling
- ferroptosis -- butyrate depletion contributes to the gut-barrier failure arm of the ferroptosis cascade
- faecalibacterium prausnitzii, bifidobacterium, blautia -- primary SCFA producers
- insulin resistance -- SCFA depletion impairs GLP-1 secretion and glucose homeostasis